Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
暂无分享,去创建一个
E. Antman | E. Braunwald | C. McCabe | E. Braunwald | A. Bayés de Luna | P. Bernink | A. Turpie | K. Fox | E. Gurfinkel | J. Lablanche | K. Fox | D. Radley | A. Turpie | A. D. Luna | J. Premmereur | C. Mccabe | D. Salein | C. Mccabe
[1] E. Antman,et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. , 1999, Circulation.
[2] Eric J Topol,et al. Platelet GPIIb-IIIa blockers , 1999, The Lancet.
[3] M. Milling,et al. molecular weight heparins , 1999 .
[4] E. Antman,et al. Low-molecular-weight heparins: an intriguing new twist with profound implications. , 1998, Circulation.
[5] H. Ostermann. Low molecular weight heparins , 1998, Der Internist.
[6] Marc Cohen,et al. One Year Follow-up of the ESSENCE Trial (enoxaparin Versus Heparin in Unstable Angina and Non-Q-Wave Myocardial Infarction) , 1998 .
[7] A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. , 1998, The New England journal of medicine.
[8] Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.
[9] L. Wallentin,et al. Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC) , 1997 .
[10] J. Nunnelee. Low-molecular-weight heparin. , 1997, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.
[11] R. Califf,et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .
[12] W. Klein,et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) , 1997, Circulation.
[13] Stgrp Capture,et al. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.
[14] E. Bramucci,et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques , 1997, The Lancet.
[15] V. Fuster,et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.
[16] Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. , 1997, Journal of the American College of Cardiology.
[17] M. Whooley,et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. , 1997, JAMA.
[18] E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.
[19] J. Shah,et al. Management of Barrett's oesophagus , 1996, The Lancet.
[20] D. Ardissino,et al. Thrombin activity and early outcome in unstable angina pectoris. , 1996, Circulation.
[21] K. Wiklund,et al. Low-molecular-weight heparin during instability in coronary artery disease , 1996 .
[22] G. Agnelli. Pharmacological activities of heparin chains: should our past knowledge be revised? , 1996, Haemostasis.
[23] J. Weitz,et al. Activation of blood coagulation by plaque rupture: mechanisms and prevention. , 1995, The American journal of cardiology.
[24] T. Meade,et al. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. , 1995, American Journal of Cardiology.
[25] T. Koh,et al. Intracoronary stenting in the treatment of acute or threatened closure in angiographically small coronary arteries (< 3.0 mm) complicating percutaneous transluminal coronary angioplasty. , 1995, The American journal of cardiology.
[26] D. Ardissino,et al. Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction , 1994, Circulation.
[27] H. Bounameaux. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases , 1994 .
[28] R. Kronmal,et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. , 1994, Circulation.
[29] D. Waters,et al. Aspirin Versus Heparin to Prevent Myocardial Infarction During the Acute Phase of Unstable Angina , 1993, Circulation.
[30] J. Hirsh. Low Molecular Weight Heparin , 1993, Thrombosis and Haemostasis.
[31] D. Waters,et al. Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.
[32] C. Madden. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: The RISC Group Lancet 336: 827–830 Oct 1990 , 1991 .
[33] The Risc Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease , 1990, The Lancet.
[34] J. Cairns,et al. Antithrombotic agents in coronary artery disease. , 1989, Chest.
[35] Aspirin, heparin, or both to treat unstable angina. , 1989, The New England journal of medicine.
[36] P. Théroux,et al. Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.